Physicians' Academy for Cardiovascular Education

Aspirin may reduce MACE in CKD patients without history of CVD

News - May 23, 2022

Effects of aspirin in primary prevention of CVD in people with chronic kidney disease (CKD): results of the TIPS3 trial

Presented at ERA congress in Paris, France by Johannes Mann (Munich, Germany)

Introduction and methods


There is limited data on the effect of aspirin on CVD in CKD patients without previous CVD. Previous analyses include ASPREE-CKD in elderly patients and HOT-CKD in patients with hypertension. In the HOT-CKD subanalysis, the benefit of aspirin on prevention of MACE and MI increased with lower eGFR. And although benefit of aspirin on MACE prevention was larger in the CKD group than in the non-CKD group in the ASPREE-CKD analysis, this finding was not statistically significant.

Aim of the study

To examine whether aspirin is effective in the prevention of CVD in people with CKD and no previous CVD (primary prevention setting).


TIPS-3 was a factorial randomized controlled trial. In this analysis of TIPS-3, data of 5712 patients randomized to aspirin (75 mg/d) or placebo were used. Mean eGFR of this population was 47 mL/min/1.73 m². CKD was defined as eGFR <60 mL/min/1.73 m² (n=983). Mean follow-up was 4.6 years.

Study endpoints

Primary outcome was a composite of MI, stroke, or CV death. Safety endpoint was bleeding.

Main results


These findings from an subanalysis of TIP-3 suggest that use of aspirin may reduce the CVD burden in patients with CKD but no history of CVD. Bleeding risk was low in this population of patients.

Johannes Mann said that we will be further informed by the ATTACK study – the first trial with the primary objective to examine aspirin in CVD-prevention in CKD-ND (non-dialysis) patients, which is expected to end in 2025.

- Our reporting is based on the information provided at the ERA congress 2022 -

Share this page with your colleagues and friends: